β-Receptor-Blocking Agents May Reverse or Prevent Diuretic-Induced Increases in Serum Low-Density Lipoprotein Cholesterol

1981 ◽  
Vol 61 (s7) ◽  
pp. 437s-439s ◽  
Author(s):  
A. Meier ◽  
H. Schiffl ◽  
P. Weidmann ◽  
R. Mordasini ◽  
W. Riesen ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Receptor Blocking ◽  
Blocking Agents ◽  
Group I ◽  
Β Blocker ◽  
Β Receptor

1. The effect of treatment with a thiazide-like diuretic alone or combined with a β-adrenoceptor blocker on serum lipoproteins was investigated in 35 patients with essential hypertension. 2. In group I (18 patients), serum low-density lipoprotein cholesterol was increased (P < 0.001) during monotherapy with chlorthalidone (100 mg/day) but not during combined chlorthalidone-β-blocker therapy. 3. This tendency was similar in subgroups studied with an inverse sequence of drug administration. In subgroup IA (11 men), a 22% increase (P < 0.01) in low-density lipoprotein cholesterol after 6 weeks of chlorthalidone was reversed after use of a β-blocker as well as chlorthalidone; in subgroup IB (five men, two post-menopausal women), low-density lipoprotein cholesterol was increased by 41% (P < 0.05) above placebo values 6 weeks after withdrawal of the β-blocker from combination therapy. 4. In group II (18 men), low-density lipoprotein cholesterol was increased by 13% (P < 0.025) after 4 weeks of monotherapy with clopamide (5 mg/day) but restored to control levels 4 weeks after addition of pindolol (10 mg/day). 5. No significant changes occurred during any treatment phase in high-density lipoprotein cholesterol. 6. Certain β-receptor blocking agents may prevent or reverse diuretic-induced increases in serum low-density lipoprotein cholesterol.

scholarly journals To Compare the Effects of Terminalia Arjuna with Rosuvastatin on Total Cholesterol and Low Density Lipoprotein Cholesterol

2016 ◽  
Vol 5 (1) ◽  
pp. 1056
Author(s):  
Ved Prakash ◽  
Vijay kumar Sehgal ◽  
Vijay Kumar Bajaj ◽  
Harcharan Singh
Keyword(s):  
Total Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Controlled Study ◽  
Terminalia Arjuna ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Group I ◽  
The Difference

<strong>Background:</strong>In India, CVD is a leading cause of death. Among the modifiable risk factors, hyperlipidemia is one of the important factors. Therefore lowering cholesterol level is a key factor in controlling this disease.<p><strong>Objectives:</strong> To compare the effect of Terminalia arjuna, an indigenous drug with Rosuvastatin on serum total cholesterol and low density lipoprotein cholesterol levels, in patients of either sex with dyslipidemia.</p><p><strong>Material and Methods:</strong> An open prospective randomized controlled study was conducted in on 60 patients for the duration of 12 weeks. Patients were distributed into two groups of 30 patients each. Group I was given Rosuvastatin 10 mg daily and group II was given capsules containing bark powder of T.arjuna 500 mg twice daily. Patients TC and LDL-C levels were performed at baseline and then repeated at 4 weeks, 8 weeks and 12 weeks. The results of both the therapies were then compared and statistically analyzed.</p><p><strong>Results:</strong> T.arjuna leads to greater reduction in mean TC level than Rosuvastatin (-14.06±8.07% vs -10.10±5.39%), (- 24.73±10.69% vs -19.42±9.98%) and (-27.89±9.25% vs - 24.74±10.02%) at 4, 8 and 12 weeks respectively. The difference between both the groups was statistically non-significant (p&gt;0.05) at 4, 8 and 12 weeks. The reduction in mean LDL-C level was also greater with T.arjuna as compared to Rosuvastatin.</p><p><strong>Conclusion:</strong> Both Rosuvastatin and T.arjuna were effective in causing significant decrease in serum TC and LDLC levels, but T.arjuna had a slight edge over Rosuvastatin as it showed greater reduction in TC and LDL-C levels as compare to Rosuvastatin. And was found to be safe and well tolerated.</p>

Short-term effects of β-adrenoceptor blocking drugs with and without cardioselectivity and intrinsic sympathomimetic activity on lipoprotein metabolism in hypertriglyceridaemic patients and in normal men

1985 ◽  
Vol 69 (6) ◽  
pp. 713-719 ◽  
Author(s):  
P. N. Durrington ◽  
W. C. Brownlee ◽  
D. M. Large
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Cholesterol Concentration ◽  
Intrinsic Sympathomimetic Activity ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Serum Triglycerides ◽  
Β Blocker ◽  
Normal Men

1. In six patients with hypertriglyceridaemia presenting whilst receiving treatment with β-adrenoreceptor blocking drugs (mean serum triglycerides 31.2 mmol/l) the half-life (t1/2) of an intravenously administered triglyceride emulsion was 32.8 ± 7.9 min (mean ± sem) on β-blocker and 22.8 ± 4.8 min after stopping β-blocker treatment. 2. In three of these patients subsequent administration of a β-blocker with intrinsic sympathomimetic activity had no effect on t1/2. 3. In a cross-over trial of placebo, atenolol (β1-blocker), propranolol (β1- and β2-blocker) and pindolol (β1- and β2-blocker with intrinsic sympathomimetic activity) in 11 normal men t1/2 was 11.8±0.9, 12.6±1.1, 14.3±1.7 and 12.4±1.1 min respectively. None of the apparent differences achieved statistical significance, but in two men marked increases in t1/2 occurred on propranolol. 4. The concentrations of serum triglycerides and very low density lipoprotein cholesterol in the normal men were, however, increased by β-blockade, most markedly by pindolol. 5. Serum high density lipoprotein (HDL) cholesterol concentration decreased in normal men on β-blockers, most clearly on atenolol and propranolol. This decrease was due to a reduction in cholesterol in the HDL2 subfraction. 6. No statistically significant effects on serum low density lipoprotein cholesterol or apolipoprotein B concentrations occurred in the normal men. 7. The doses of atenolol and propranolol used in this study were equipotent as judged by the heart rate response to exercise.

scholarly journals ASSESSMENT OF LIPID METABOLISM IN PATIENTS WITH CORONARY ARTERY DISEASE AND GENERALIZED PERIODONTITIS

2021 ◽  
Vol 65 (2) ◽  
Author(s):  
Oksana Skybchyk ◽  
◽  
Orest Chevtchik ◽  
Tetiana Solomenchuk ◽  
Olesya Martovlos (Hodovana) ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Lipid Metabolism ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Gingival Health ◽  
Group I ◽  
Artery Disease

Introduction. It has been assumed that generalized periodontitis (GP) adversely affects the qualitative and quantitative composition of plasma lipids and lipoproteins. On the other hand, periodontal treatment and reduction of general periodontal pocket infection in patients with GP are associated with a decrease in total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C) and triglycerides (TG). The aim of the study was to conduct a comparative assessment of the state of lipid metabolism in patients with coronary artery disease (CAD) depending on the GP severity. Methods. The study included 101 patients (mean±SD age - 58.2 ± 8.3 years) with CAD and GP, 58 men (57.4%) and 43 women (42.6%). According to the severity of GP, study participants were divided into 3 groups: group I - patients with CAD and GP stage I (initial periodontitis), group II - patients with CAD and GP stage II (moderate periodontitis) and group III - patients with CAD and GP stage III and IV (severe periodontitis). The control group included 9 patients with CAD and clinical gingival health on an intact periodontium (mean±SD age - 56.3 ± 6.1 years), 5 men (55.6%) and 4 women (44.4%). The diagnosis of CAD and the results of lipid metabolism were obtained by analyzing the inpatient medical records. Results. It was revealed that the values of TC, LDL-C, very low-density lipoprotein-cholesterol (VLDL-C), TG and atherogenic coefficient (AC) were lower in the group of patients with CAD and clinical gingival health compared to the level of the corresponding indicators in the groups of patients with CAD and GP (p<0.05). In the analysis of lipid profile in patients with CAD and GP of varying severity, it was found that the average levels of TC, LDL-C, and AC in the subjects of group I were significantly lower compared to the corresponding indicators of groups II and III (p<0.05). There was no statistical difference in the values of lipid metabolism in groups II and III (p>0.05). No significant difference was found in high-density lipoprotein-cholesterol (HDL-C) levels between the comparison groups including the patients with CAD and clinical gingival health (p>0.05), as well as the gender characteristics of the analyzed indicators in the examined patients. Conclusions. Average levels of TC, LDL-C, and AC in patients with CAD and GP increase with increasing destructive-inflammatory changes in periodontal tissues, therefore, with the severity of GP indicating the progression of atherogenesis along with the increased inflammatory process in the periodontium

Sign in / Sign up

Export Citation Format

Share Document